Compare Eli Lilly And Co (LLY) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Riot Platforms Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Riot Platforms Inc trades at $16.9 (market cap $6.32B). The key difference: Eli Lilly And Co is far larger — about 164.6× Riot Platforms Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Riot Platforms Inc for 16 Days on average.
| LLY | RIOT | |
|---|---|---|
Market Cap | $1.04T | $6.32B |
Volume | 3,064,878 | 30,571,756 |
Sector | Health | Financials |
52-Week High | $1.28K | $28.67 |
52-Week Low | $799.57 | $11.83 |
Typical Hold Time | 93 Days | 16 Days |
Enterprise Value | $1.09T | $6.73B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
RIOT Platforms trades at $16.885, down 8.93% on the day, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported significant losses with a net income margin of -196.28% in 2026, though revenue grew to $675 million. Recent strategic shifts toward AI data center leasing, including a $9.1 billion contract, highlight transformation efforts amid challenging profitability.
While analyst consensus remains strongly bullish with a $31.64 price target, substantial execution risks and persistent negative earnings pose challenges. The stock's outlook hinges on successful monetization of AI infrastructure contracts and improved operational efficiency to stem cash flow deficits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
